Uj perspektívák a krónikus lymphoid leukaemia prognózisának megállapításában és kezelésében.

Translated title of the contribution: New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia

Béla Telek, László Rejto, Attila Kiss, Leonóra Méhes, Péter Batár, M. Udvardy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic lymphocytic leukaemia is a disease with a variable clinical course and prognosis. New prognostic factors like immunoglobulin gene mutational status, cytogenetic abnormalities, CD38 and ZAP70 expression of malignant cells have been described recently. Conventional and biological prognostic factors allow to identify patients with unfavorable prognosis at early stage. Purin analogues, fludarabine and fludarabine based combinations can achieve complete hematological remission in approximately one third of patients with chronic lymphocytic leukaemia. Chemoimmunotherapy (most experience is obtained by combination of fludarabine + cyclophosphamide + rituximab) can increase not only complete remission rate, but also induce molecular remission in some cases. Stem cell transplantation as well as early and effective chemotherapy are curative choices of treatment in patients with chronic lymphocytic leukaemia.

Original languageHungarian
Pages (from-to)1795-1800
Number of pages6
JournalOrvosi Hetilap
Volume145
Issue number35
Publication statusPublished - Aug 29 2004

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Immunoglobulin Genes
Biological Factors
Stem Cell Transplantation
Therapeutics
Chromosome Aberrations
Cyclophosphamide
Drug Therapy
fludarabine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Uj perspektívák a krónikus lymphoid leukaemia prognózisának megállapításában és kezelésében. / Telek, Béla; Rejto, László; Kiss, Attila; Méhes, Leonóra; Batár, Péter; Udvardy, M.

In: Orvosi Hetilap, Vol. 145, No. 35, 29.08.2004, p. 1795-1800.

Research output: Contribution to journalArticle

Telek, B, Rejto, L, Kiss, A, Méhes, L, Batár, P & Udvardy, M 2004, 'Uj perspektívák a krónikus lymphoid leukaemia prognózisának megállapításában és kezelésében.', Orvosi Hetilap, vol. 145, no. 35, pp. 1795-1800.
Telek, Béla ; Rejto, László ; Kiss, Attila ; Méhes, Leonóra ; Batár, Péter ; Udvardy, M. / Uj perspektívák a krónikus lymphoid leukaemia prognózisának megállapításában és kezelésében. In: Orvosi Hetilap. 2004 ; Vol. 145, No. 35. pp. 1795-1800.
@article{72064ebd64574de4929e4724e4dfcb7c,
title = "Uj perspekt{\'i}v{\'a}k a kr{\'o}nikus lymphoid leukaemia progn{\'o}zis{\'a}nak meg{\'a}llap{\'i}t{\'a}s{\'a}ban {\'e}s kezel{\'e}s{\'e}ben.",
abstract = "Chronic lymphocytic leukaemia is a disease with a variable clinical course and prognosis. New prognostic factors like immunoglobulin gene mutational status, cytogenetic abnormalities, CD38 and ZAP70 expression of malignant cells have been described recently. Conventional and biological prognostic factors allow to identify patients with unfavorable prognosis at early stage. Purin analogues, fludarabine and fludarabine based combinations can achieve complete hematological remission in approximately one third of patients with chronic lymphocytic leukaemia. Chemoimmunotherapy (most experience is obtained by combination of fludarabine + cyclophosphamide + rituximab) can increase not only complete remission rate, but also induce molecular remission in some cases. Stem cell transplantation as well as early and effective chemotherapy are curative choices of treatment in patients with chronic lymphocytic leukaemia.",
author = "B{\'e}la Telek and L{\'a}szl{\'o} Rejto and Attila Kiss and Leon{\'o}ra M{\'e}hes and P{\'e}ter Bat{\'a}r and M. Udvardy",
year = "2004",
month = "8",
day = "29",
language = "Hungarian",
volume = "145",
pages = "1795--1800",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "35",

}

TY - JOUR

T1 - Uj perspektívák a krónikus lymphoid leukaemia prognózisának megállapításában és kezelésében.

AU - Telek, Béla

AU - Rejto, László

AU - Kiss, Attila

AU - Méhes, Leonóra

AU - Batár, Péter

AU - Udvardy, M.

PY - 2004/8/29

Y1 - 2004/8/29

N2 - Chronic lymphocytic leukaemia is a disease with a variable clinical course and prognosis. New prognostic factors like immunoglobulin gene mutational status, cytogenetic abnormalities, CD38 and ZAP70 expression of malignant cells have been described recently. Conventional and biological prognostic factors allow to identify patients with unfavorable prognosis at early stage. Purin analogues, fludarabine and fludarabine based combinations can achieve complete hematological remission in approximately one third of patients with chronic lymphocytic leukaemia. Chemoimmunotherapy (most experience is obtained by combination of fludarabine + cyclophosphamide + rituximab) can increase not only complete remission rate, but also induce molecular remission in some cases. Stem cell transplantation as well as early and effective chemotherapy are curative choices of treatment in patients with chronic lymphocytic leukaemia.

AB - Chronic lymphocytic leukaemia is a disease with a variable clinical course and prognosis. New prognostic factors like immunoglobulin gene mutational status, cytogenetic abnormalities, CD38 and ZAP70 expression of malignant cells have been described recently. Conventional and biological prognostic factors allow to identify patients with unfavorable prognosis at early stage. Purin analogues, fludarabine and fludarabine based combinations can achieve complete hematological remission in approximately one third of patients with chronic lymphocytic leukaemia. Chemoimmunotherapy (most experience is obtained by combination of fludarabine + cyclophosphamide + rituximab) can increase not only complete remission rate, but also induce molecular remission in some cases. Stem cell transplantation as well as early and effective chemotherapy are curative choices of treatment in patients with chronic lymphocytic leukaemia.

UR - http://www.scopus.com/inward/record.url?scp=16544393176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544393176&partnerID=8YFLogxK

M3 - Article

C2 - 15493222

AN - SCOPUS:16544393176

VL - 145

SP - 1795

EP - 1800

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 35

ER -